Compare HURC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURC | AGEN |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.3M | 126.2M |
| IPO Year | N/A | 2000 |
| Metric | HURC | AGEN |
|---|---|---|
| Price | $17.43 | $2.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 30.7K | ★ 883.1K |
| Earning Date | 03-06-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $178,554,000.00 | $106,829,000.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $68.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.19 | $1.38 |
| 52 Week High | $23.45 | $7.34 |
| Indicator | HURC | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.33 |
| Support Level | N/A | $2.71 |
| Resistance Level | N/A | $2.96 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 8.33 |
Hurco Companies Inc is an international industrial technology company that designs, manufactures, and sells computerized (CNC) machine tools for the metal cutting industry through a international sales and distribution network. Its proprietary control systems and software are sold as integral components of its machine tools. The Company also provides machine tool components, automation solutions, software options, upgrades, accessories, replacement parts, and related support services. It operates in the Americas, Europe, and Asia Pacific, with the Americas contributing the majority of revenue. Its core products include vertical and horizontal machining centers (mills), turning centers (lathes), and toolroom machines.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).